Table 1.
Study population characteristics, with regards to HD patients’ sex; for the whole study group and among those for whom both alleles within the HTT gene were known.
| All | Men | Women | P | |
|---|---|---|---|---|
| Males vs females | ||||
| 1Study group | N = 3723 | N = 1785 (47.95%) | N = 1938 (52.05%) | |
| Age at onset (rater’s estimate) | ||||
|
Median (q1–q3) Mean, SD |
44 (35–52) 43.96, 12.29 |
45 (36–53) 44.61, 12.30 |
0.0793# | |
| First symptoms | ||||
| 1 (motor) | N = 936 (52.82%) | N = 990 (51.48%) | 0.2294* | |
| 2 (cognitive) | N = 140 (7.90%) | N = 129 (6.71%) | ||
| 3 (psychiatric) | N = 358 (20.20%) | N = 402 (20.90%) | ||
| 4 (oculomotor) | – | N = 3 (0.16%) | ||
| 5 (other) | N = 20 (1.13%) | N = 19 (0.99%) | ||
| 6 (mixed) | N = 319 (17.95%) | N = 380 (19.76%) | ||
| Expanded allele length | ||||
|
Median (q1–q3) Mean, SD |
43 (42–46) 44.31, 4.26 |
43 (42–46) 44.41, 4.41 |
0.4376# | |
| 2Subgroup with data on normal allele length | N = 3643 | N = 1749 | N = 1894 | |
| Normal allele length | ||||
|
Median (q1–q3) Mean, SD |
18 (17–20) 18.49, 3.19 |
17 (17–19) 18.41, 3.28 |
0.1431# | |
1Data restricted to subjects whose expanded allele ≥ CAG36, normal allele < CAG36 (if available), for whom sex, AO, number of (CAG)n was available. Homozygous subjects (genotype: 42/37, 44/36, 44/39, 45/45, 49/39, 54/37, 54/37, 65/36) were excluded.
2Data restricted to subjects for whom numbers of (CAG)n within both alleles were available.
#Wilcoxon Rank Sum Test.
*Chi-square.